Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Reduced by Zacks Research

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities research analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for shares of Esperion Therapeutics in a report issued on Tuesday, October 8th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings of ($0.16) per share for the quarter, down from their previous estimate of ($0.15). The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.04) per share. Zacks Research also issued estimates for Esperion Therapeutics' Q2 2025 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.25) EPS and FY2026 earnings at ($0.02) EPS.

ESPR has been the subject of a number of other research reports. Bank of America cut shares of Esperion Therapeutics from a "neutral" rating to an "underperform" rating and cut their price target for the company from $2.90 to $2.50 in a research note on Thursday, June 20th. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 2nd. StockNews.com upgraded shares of Esperion Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, October 5th. Finally, Needham & Company LLC dropped their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating on the stock in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Esperion Therapeutics currently has an average rating of "Hold" and an average target price of $8.17.

Esperion Therapeutics Price Performance

NASDAQ:ESPR traded up $0.08 during trading hours on Friday, reaching $1.97. 3,461,366 shares of the stock were exchanged, compared to its average volume of 6,407,091. Esperion Therapeutics has a twelve month low of $0.70 and a twelve month high of $3.40. The firm has a 50 day moving average of $1.82 and a 200 day moving average of $2.19. The stock has a market cap of $386.57 million, a PE ratio of -2.29 and a beta of 1.00.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.10. The business had revenue of $73.83 million during the quarter, compared to analyst estimates of $51.90 million.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in Esperion Therapeutics by 71.8% during the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company's stock valued at $23,655,000 after purchasing an additional 3,688,796 shares in the last quarter. Bellevue Group AG increased its stake in Esperion Therapeutics by 136.5% during the 1st quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company's stock valued at $26,650,000 after purchasing an additional 5,739,800 shares in the last quarter. SG Americas Securities LLC bought a new stake in Esperion Therapeutics during the 1st quarter valued at $69,000. Marshall Wace LLP increased its stake in Esperion Therapeutics by 94.2% during the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company's stock valued at $9,554,000 after purchasing an additional 2,087,635 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Esperion Therapeutics by 3,278.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company's stock valued at $1,271,000 after purchasing an additional 555,382 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.